Analysts Expect Cerus Co. (CERS) to Announce -$0.12 Earnings Per Share

Equities analysts expect that Cerus Co. (NASDAQ:CERS) will report earnings of ($0.12) per share for the current quarter, Zacks reports. Zero analysts have made estimates for Cerus’ earnings, with estimates ranging from ($0.12) to ($0.11). Cerus reported earnings of ($0.13) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 7.7%. The firm is expected to report its next quarterly earnings report on Tuesday, March 6th.

On average, analysts expect that Cerus will report full year earnings of ($0.58) per share for the current fiscal year, with EPS estimates ranging from ($0.62) to ($0.54). For the next fiscal year, analysts forecast that the business will post earnings of ($0.44) per share, with EPS estimates ranging from ($0.45) to ($0.42). Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that cover Cerus.

A number of brokerages recently issued reports on CERS. BTIG Research reissued a “hold” rating on shares of Cerus in a research report on Thursday, January 25th. BidaskClub raised shares of Cerus from a “strong sell” rating to a “sell” rating in a report on Friday, January 5th. Zacks Investment Research cut shares of Cerus from a “hold” rating to a “sell” rating in a report on Tuesday, January 30th. Finally, Cantor Fitzgerald set a $5.00 target price on shares of Cerus and gave the stock a “buy” rating in a report on Monday, January 8th. Three investment analysts have rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $5.83.

Institutional investors have recently modified their holdings of the business. Premier Asset Management LLC purchased a new position in Cerus in the third quarter worth about $348,000. Vanguard Group Inc. grew its stake in shares of Cerus by 3.9% in the second quarter. Vanguard Group Inc. now owns 4,892,503 shares of the biotechnology company’s stock worth $12,281,000 after acquiring an additional 184,076 shares during the period. Elk Creek Partners LLC grew its stake in shares of Cerus by 6.8% in the third quarter. Elk Creek Partners LLC now owns 6,128,026 shares of the biotechnology company’s stock worth $16,730,000 after acquiring an additional 388,741 shares during the period. First Midwest Bank Trust Division grew its stake in shares of Cerus by 50.3% in the third quarter. First Midwest Bank Trust Division now owns 1,078,277 shares of the biotechnology company’s stock worth $2,944,000 after acquiring an additional 360,785 shares during the period. Finally, Northern Trust Corp grew its stake in shares of Cerus by 3.2% in the second quarter. Northern Trust Corp now owns 1,269,773 shares of the biotechnology company’s stock worth $3,186,000 after acquiring an additional 39,684 shares during the period. 51.52% of the stock is owned by institutional investors and hedge funds.

Shares of Cerus (NASDAQ CERS) traded down $0.08 during midday trading on Monday, reaching $3.85. 741,774 shares of the company were exchanged, compared to its average volume of 1,920,000. Cerus has a one year low of $1.93 and a one year high of $5.43. The stock has a market cap of $444.89, a PE ratio of -6.53 and a beta of 2.22. The company has a debt-to-equity ratio of 0.80, a quick ratio of 3.11 and a current ratio of 3.71.

TRADEMARK VIOLATION NOTICE: This piece of content was originally published by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/02/12/analysts-expect-cerus-co-cers-to-announce-0-12-earnings-per-share.html.

Cerus Company Profile

Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

Get a free copy of the Zacks research report on Cerus (CERS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Cerus (NASDAQ:CERS)

Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply